跳转至内容
Merck

C2150000

胆钙化醇

European Pharmacopoeia (EP) Reference Standard

别名:

(+)-维生素 D3, 活化7-脱氢胆固醇, 活化7-脱氢胆甾醇, 胆骨化醇

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H44O
CAS号:
分子量:
384.64
Beilstein:
2339331
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

生物源

synthetic

等級

pharmaceutical primary standard

agency

EP

API 家族

cholecalciferol

形狀

solid

製造商/商標名

EDQM

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

mp

83-86 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

−20°C

SMILES 字串

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

InChI 密鑰

QYSXJUFSXHHAJI-YRZJJWOYSA-N

基因資訊

human ... VDR(7421)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Cholecalciferol, also referred to as vitamin D3, promotes the absorption of calcium and phosphorus in the body to regulate bone growth. It is most commonly found in humans and animals and is produced in our skin when exposed to sunlight. It is used to treat and prevent bone disorders (such as rickets, osteomalacia).

應用

Cholecalciferol for system suitability may be used as an analytical reference standard for the determination of the analyte in pharmaceutical formulations by liquid chromatography.

生化/生理作用

维生素 D 借以发挥作用的受体是配体依赖性转录因子超家族的成员。调控正常细胞和癌细胞的增殖和分化。对乳腺癌、结肠癌和前列腺癌细胞具有抗增殖和抗转移作用。肠和骨骼中的活化维生素 D 受体维持着钙的吸收和平衡。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Cholecalciferol
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 246(6), 2058-2059 (2013)
Vitamin D is not directly necessary for bone growth and mineralization
Underwood JL and DeLuca HF
American Journal of Physiology. Endocrinology and Metabolism, 246(6), E493-E498 (1984)
Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial
Trivedi DP, et al.
BMJ (Clinical Research ed.), 326(7387), 469-469 (2003)
Sina Gallo et al.
JAMA, 309(17), 1785-1792 (2013-05-02)
Vitamin D supplementation in infancy is required to support healthy bone mineral accretion. A supplement of 400 IU of vitamin D per day is thought to support plasma 25-hydroxyvitamin D (25[OH]D) concentrations between 40 and 50 nmol/L; some advocate 75
Sara S Oberhelman et al.
Mayo Clinic proceedings, 88(12), 1378-1387 (2013-12-03)
To determine whether a single monthly supplement is as effective as a daily maternal supplement in increasing breast milk vitamin D to achieve vitamin D sufficiency in their infants. Forty mothers with exclusively breast-fed infants were randomized to receive oral

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门